The Latin America, Middle East and Africa Serum Separation Gel Market would witness market growth of 9.0% CAGR during the forecast period (2024-2031).
The Brazil market dominated the LAMEA Serum Separation Gel Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $304.5 million by 2031. The Argentina market is showcasing a CAGR of 9.6% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 8.7% during (2024 - 2031).
Serum separation gel is employed in various biotechnology applications, including producing recombinant proteins, monoclonal antibodies, vaccines, and cell culture media. Serum-derived components obtained through serum separation gel are used as supplements in cell culture and fermentation processes to support cell growth, proliferation, and protein production. High-quality serum samples obtained using serum separation gel are critical for maintaining the consistency and performance of biotechnological processes.
Additionally, Serum separation gel is also used in veterinary medicine for diagnostic testing and research. Veterinary laboratories use serum samples obtained with serum separation gel to diagnose diseases, monitor animal health, and conduct research studies relevant to animal physiology, pathology, and pharmacology.
As per the National Library of Medicine, the Middle East has a high rate of cardiovascular disease (10.1%). In this region, the prevalence of dyslipidemia (43.3%) is double that of hypertension (26.2%) and diabetes mellitus (16%). Multifaceted interventions are desperately needed in this region for CVD primary prevention. The Middle East's primary causes of morbidity and mortality are cardiovascular diseases, which include stroke, hypertension, and coronary artery disease.
Middle Eastern countries are investing in healthcare infrastructure, technology, and services to address the healthcare needs of their growing populations. Healthcare organizations, governmental agencies, and non-profit organizations in the Middle East conduct awareness campaigns and screening programs to promote cardiovascular health and prevent heart disease. Thus, due to these aspects, the serum separation gel market will expand across the LAMEA region in upcoming years.
Based on Product Type, the market is segmented into Serum Separation Gel Integrated with Tube, and Serum Separation Gel Integrated without Tube. Based on End User, the market is segmented into Blood Bank, Hospital, Pharmaceutical & Companies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Serum Separation Gel Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $304.5 million by 2031. The Argentina market is showcasing a CAGR of 9.6% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 8.7% during (2024 - 2031).
Serum separation gel is employed in various biotechnology applications, including producing recombinant proteins, monoclonal antibodies, vaccines, and cell culture media. Serum-derived components obtained through serum separation gel are used as supplements in cell culture and fermentation processes to support cell growth, proliferation, and protein production. High-quality serum samples obtained using serum separation gel are critical for maintaining the consistency and performance of biotechnological processes.
Additionally, Serum separation gel is also used in veterinary medicine for diagnostic testing and research. Veterinary laboratories use serum samples obtained with serum separation gel to diagnose diseases, monitor animal health, and conduct research studies relevant to animal physiology, pathology, and pharmacology.
As per the National Library of Medicine, the Middle East has a high rate of cardiovascular disease (10.1%). In this region, the prevalence of dyslipidemia (43.3%) is double that of hypertension (26.2%) and diabetes mellitus (16%). Multifaceted interventions are desperately needed in this region for CVD primary prevention. The Middle East's primary causes of morbidity and mortality are cardiovascular diseases, which include stroke, hypertension, and coronary artery disease.
Middle Eastern countries are investing in healthcare infrastructure, technology, and services to address the healthcare needs of their growing populations. Healthcare organizations, governmental agencies, and non-profit organizations in the Middle East conduct awareness campaigns and screening programs to promote cardiovascular health and prevent heart disease. Thus, due to these aspects, the serum separation gel market will expand across the LAMEA region in upcoming years.
Based on Product Type, the market is segmented into Serum Separation Gel Integrated with Tube, and Serum Separation Gel Integrated without Tube. Based on End User, the market is segmented into Blood Bank, Hospital, Pharmaceutical & Companies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Becton, Dickinson, and Company
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Agilent Technologies, Inc.
- Siemens Healthineers AG (Siemens AG)
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Sysmex Corporation
- Charles River Laboratories International, Inc.
- QuidelOrtho Corporation
Market Report Segmentation
By Product Type- Serum Separation Gel Integrated with Tube
- Serum Separation Gel Integrated without Tube
- Blood Bank
- Hospital
- Pharmaceutical & Companies
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Serum Separation Gel Market by Product Type
Chapter 5. LAMEA Serum Separation Gel Market by End User
Chapter 6. LAMEA Serum Separation Gel Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Becton, Dickinson, and Company
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Agilent Technologies, Inc.
- Siemens Healthineers AG (Siemens AG)
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Sysmex Corporation
- Charles River Laboratories International, Inc.
- QuidelOrtho Corporation
Methodology
LOADING...
